Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent reactions, 3′ end processing and strand transfer. Compounds that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication. To characterize the molecular basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs. These studies focused on investigating the role of the conserved carboxylate and metal binding. We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor. Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg 2+ . The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical metal cofactor(s). These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The INSTI pharmacophore consists of a metal chelating core - generally a co-planar triad of oxygen atoms - and a halobenzyl side chain (Fig. 5A, shown in red and blue, respectively)156.”
From Structure and function of retroviral integrase (2022) · cites this paper as [156]
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Self-citationDNA Polymerases: Structural Diversity and Common Mechanisms
Steitz, T. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17395 · Cited by 848
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570
Goldgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., & Davies, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13040 · Cited by 496
Three-Dimensional Structure of the Tn 5 Synaptic Complex Transposition Intermediate
Davies, D. R., Goryshin, I. Y., Reznikoff, W. S., & Rayment, I. (2000) · Science · doi:10.1126/science.289.5476.77 · Cited by 427
Bushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410
Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium
Goldgur, Y., Dyda, F., Hickman, A. B., Jenkins, T. M., Craigie, R., & Davies, D. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9150 · Cited by 380
Sherman, P. A., & Fyfe, J. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5119 · Cited by 334
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317
Self-citation
Research works printed but not linked: 1
- P O Brown Retroviruses, eds J M Coffin, S H Hughes, H E Varmus (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 161–203 (1997).
Cited by
Items 201–300 of 443
Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors
Yuan, H., & Parrill, A. L. (2004) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2004.10.003 · Cited by 21
Langford, H. M., Williams, P. D., Homnick, C. F., Vacca, J. P., Felock, P. J., Stillmock, K. A., Witmer, M. V., Hazuda, D. J., Gabryelski, L. J., & Schleif, W. A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.049 · Cited by 21
Self-citationCvijetić, I., Verbić, T. Ž., de Resende, P. E., Stapleton, P. D., Gibbons, S., Juranić, I. O., Drakulić, B. J., & Zloh, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.045 · Cited by 21
“IN active site contains Mg2þ/Asp motif and diketo acids IN inhibitors are able to sequestrate Mg2þ ion from the active site [7].”
BackgroundNew antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?
Ndashimye, E., Reyes, P. S., & Arts, E. J. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac040 · Cited by 25
Ferro, S., Luca, L. D., Barreca, M. L., Grazia, S. D., Christ, F., Debyser, Z., & Chimirri, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.063 · Cited by 20
HIV-1 Integrase Inhibitor-Inspired Antibacterials Targeting Isoprenoid Biosynthesis
Zhang, Y., Lin, F., Li, K., Zhu, W., Liu, Y.-L., Cao, R., Pang, R., Lee, E., Axelson, J. C., Hensler, M. E., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300038t · Cited by 21
Computer Tools in the Discovery of HIV-1 Integrase Inhibitors
Liao, C., & Nicklaus, M. C. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.193 · Cited by 21
Pleiotropic Nature of HIV‐1 Integrase Mutations
Engelman, A. (2011) · HIV‐1 Integrase · doi:10.1002/9781118015377.ch6 · Cited by 20
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
Richetta, C., Tu, N. Q., & Delelis, O. (2022) · Viruses · doi:10.3390/v14122591 · Cited by 24
The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function
Singer, M. R., Dinh, T., Levintov, L., Annamalai, A. S., Rey, J. S., Briganti, L., Cook, N., Pye, V. E., Taylor, I. A., Kim, K., et al. (2023) · mBio · doi:10.1128/mbio.03560-22 · Cited by 21
Kim, J., Kim, K.-S., Kim, D., & Chong, Y. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00730.x · Cited by 19
Wiscount, C. M., Williams, P. D., Tran, L. O., Embrey, M. W., Fisher, T. E., Sherman, V., Homnick, C. F., Staas, D. D., Lyle, T. A., Wai, J. S. M., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.037 · Cited by 19
Self-citationHIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action
Pandey, K. K., & Grandgenett, D. P. (2008) · Retrovirology Research and Treatment · doi:10.4137/rrt.s1081 · Cited by 23
“Retrovirology: Research and Treatment 2008:2 for the catalysis [12].”
Nair, V., Uchil, V. R., & Neamati, N. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.093 · Cited by 20
Design, synthesis, and anti-integrase activity of catechol–DKA hybrids
Maurin, C., Bailly, F., Mbemba, G., Mouscadet, J. F., & Cotelle, P. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.039 · Cited by 20
Cox, A. G., & Nair, V. (2006) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020601700604 · Cited by 21
“Thus, it has been proposed that an additional Mg2+ or Mn2+ ion can be coordinated between Asp64 and Glu152 once HIV-1 IN binds its DNA substrates (Grobler et al., 2002; Marchand et al., 2003).”
BackgroundAromatic interaction profile to understand the molecular basis of raltegravir resistance
Balaraju, T., Kumar, A., Bal, C., Chattopadhyay, D., Jena, N., Bal, N. C., & Sharon, A. (2012) · Structural Chemistry · doi:10.1007/s11224-012-0181-1 · Cited by 18
“The cofactor for the CCD of the IN enzyme comprises two metal ions (mostly magnesium) [15] that coordinates with conserved catalytic residues D64, D116, and E152 (DDE) [16, 17] and binds with vDNA followed by the insertion into a host DNA (hDNA).”
Background2-Substituted-4,5-Dihydroxypyrimidine-6-Carboxamide Antiviral Targeted Libraries
Boyd, V. A., Mason, J. N., Hanumesh, P., Price, J. E., Russell, C. J., & Webb, T. R. (2009) · Journal of Combinatorial Chemistry · doi:10.1021/cc900111u · Cited by 18
The successes and failures of HIV drug discovery
Hashimoto, C., Tanaka, T., Narumi, T., Nomura, W., & Tamamura, H. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.611129 · Cited by 19
“, NJ, USA), which have a two magnesium-binding pharmacophore, have been found as first-generation IN inhibitors (Figure 4B) [76].”
BackgroundBiochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
Nilavar, N. M., Paranjape, A. M., & Raghavan, S. C. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0281-4 · Cited by 18
Quashie, P. K., Han, Y.-S., Hassounah, S. A., Mésplède, T., & Wainberg, M. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128310 · Cited by 21
“The coordination of divalent Mg/Mn ions by the D64D116E152 residues is critical for IN activity [6] and this has led to the development of the cation-chelating diketoacid derivative compounds [7, 8] that are currently used as IN strand transfer inhibitors (INSTIs), such as raltegravir (RAL) [9] and elvitegravir (EVG)…”
BackgroundMiri, L., Bouvier, G., Kettani, A., Mikou, A., Wakrim, L., Nilges, M., & Malliavin, T. E. (2013) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24412 · Cited by 21
Anti-HIV Agents: Current Status and Recent Trends
Geronikaki, A. A., Eleftheriou, P. T., & Poroikov, V. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2015_5001 · Cited by 19
Wainberg, M. A. (2012) · Scientifica · doi:10.6064/2012/238278 · Cited by 18
“ese drugs contain a halogenated phenyl group that invades the catalytic pocket and displaces the 3 viral end [236, 240] and three coplanar oxygen atoms that chelate the divalent ions within the catalytic pocket, thus inhibiting the activity of the catalytic DDE triad [211, 213, 232, 241–243].”
BackgroundHombrouck, A., Hantson, A., Remoortel, B. V., Michiels, M., Vercammen, J., Rhodes, D., Tetz, V., Engelborghs, Y., Christ, F., Debyser, Z., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm101 · Cited by 19
“The mode of action of DKAs is based on the interaction with critical, divalent metal ions in the IN active site, resulting in a subsequent sequestration of the metal cofactor.(28) Not surprisingly, mutations that result in resistance to these prototype inhibitors map to the IN active site proximal to residues that coo…”
Theoretical study on the HIV-1 integrase–5CITEP complex based on polarized force fields
Wei, C., Mei, Y., & Zhang, D. (2010) · Chemical Physics Letters · doi:10.1016/j.cplett.2010.06.048 · Cited by 16
Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration
Grobler, J. A., Stillmock, K. A., & Hazuda, D. J. (2009) · Methods · doi:10.1016/j.ymeth.2009.03.002 · Cited by 15
Self-citationKim, J., Kim, K.-S., Lee, H. S., Park, K., Park, S. Y., Kang, S.-Y., Lee, S. J., Park, H. S., Kim, D., & Chong, Y. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.008 · Cited by 16
Tong, J., Pei, Z., Wang, X. S., & Yingji, W. (2017) · Journal of Chemometrics · doi:10.1002/cem.2934 · Cited by 15
Mullins, N. D., Maguire, N. M., Ford, A., Das, K., Arnold, E., Balzarini, J. M., & Maguire, A. R. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02507a · Cited by 16
Discovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4
Bagossi, P., Bander, P., Bozóki, B., & Tőzsér, J. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.97 · Cited by 19
Goffinet, C., Allespach, I., Oberbremer, L., Golden, P. L., Foster, S. A., Johns, B. A., Weatherhead, J. G., Novick, S. J., Chiswell, K., Garvey, E. P., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00683-09 · Cited by 20
“All two-metalbinding INIs, for example, raltegravir and naphthyridinone analogues, such as GSK364735 (14), selectively inhibit this second step (21).”
BackgroundMetal-dependent inhibition of HIV-1 integrase by 5CITEP inhibitor: A theoretical QM/MM approach
do Nascimento, J. L. M., Silva, J. R. A., Lameira, J., & Alves, C. N. (2013) · Chemical Physics Letters · doi:10.1016/j.cplett.2013.08.006 · Cited by 16
Burlein, C., Wang, C., Xu, M., Bhatt, T., Stahlhut, M. W., Ou, Y., Adam, G. C., Heath, J., Klein, D. J., Sanders, J. M., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00550 · Cited by 14
Self-citationHadda, T. B., Fathi, J., Chafchaouni, I., Masand, V. H., Charrouf, Z., CHOHAN, Z. H., Jawarkar, R. D., Fergoug, T., & Warad, I. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0120-0 · Cited by 14
“…of the two pharmacophore sites is formed hence, causing partial or complete inactivation of HIV IN enzyme (Savarino, 2007; Nowotny and Yang, 2006; Dubey et al., 2007; Lee, 2009; Johns et al., 2004; Kawasuji et al., 2006a, b; Garvey et al., 2008; Grobler et al., 2002; Mouscadet et al., 2010).”
BackgroundMultifunctional facets of retrovirus integrase
Grandgenett, D. P., Pandey, K. K., Bera, S., & Aihara, H. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.83 · Cited by 23
Isaacs, D., Mikasi, S. G., Obasa, A. E., Ikomey, G. M., Shityakov, S., Cloete, R. E. A., & Jacobs, G. B. (2020) · Viruses · doi:10.3390/v12090936 · Cited by 14
“The same active site in IN, which contains a retroviral highly conserved DDE motif and magnesium ions, performs both activities [5,6].”
BackgroundNunthaboot, N., Pianwanit, S., Parasuk, V., Ebalunode, J. O., Briggs, J. M., & Kokpol, S. U. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.108464 · Cited by 14
“Moreover, the second metal has been proposed to present in the HIV-1 IN active site once it binds with the substrate (4,5).”
BackgroundKehlenbeck, S., Betz, U. A. K., Birkmann, A., Fast, B., Goller, A., Henninger, K., Lowinger, T. B., Marrero, D., Paessens, A., Paulsen, D., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00306-06 · Cited by 14
“For DKA-like inhibitors, a two-metal-binding model has been proposed in which the diketo acid pharmacophore coordinates two divalent metal ions in the catalytic site of the integrase donor substrate complex, thereby competing with the target DNA (25).”
BackgroundInfluentialIntegrase: An Important Therapeutic Target in the Fight Against HIV/AIDS Infection
Santos, M. L. A., Albuquerque, M. G., & de Brito, M. A. (2014) · Revista Virtual de Química · doi:10.5935/1984-6835.20140058 · Cited by 25
Bulged DNA substrates for identifying poxvirus resolvase inhibitors
Culyba, M. J., Hwang, Y., Attar, S., Madrid, P. B., Bupp, J. E., Huryn, D. M., Sanchez, L., Grobler, J. A., Miller, M. D., & Bushman, F. D. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks325 · Cited by 14
“These inhibitors contain a metal chelating pharmacophore that is thought to disrupt catalysis by binding divalent metal-ion cofactors at the enzyme active site (12,13).”
Self-citationTautomerism and Magnesium Chelation of HIV‐1 Integrase Inhibitors: A Theoretical Study
Liao, C., & Nicklaus, M. C. (2010) · ChemMedChem · doi:10.1002/cmdc.201000039 · Cited by 13
Dalton, N., Gordon, C. P., Boyle, T. P., Vandegraaff, N., Deadman, J. J., Rhodes, D. I., Coates, J. A. V., Pyne, S. G., Keller, P. A., & Bremner, J. B. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00950f · Cited by 13
Current Clinical Treatments of AIDS
Murphy, E., Jimenez, H. R., & Smith, S. M. (2008) · Advances in pharmacology · doi:10.1016/s1054-3589(07)56002-3 · Cited by 13
7-O-Arylmethylgalangin as a novel scaffold for anti-HCV agents
Lee, H. S., Park, K., Lee, C., Lee, B., Kim, D., & Chong, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.012 · Cited by 13
Structure-Driven Discovery of α,γ-Diketoacid Inhibitors Against UL89 Herpesvirus Terminase
Bongarzone, S., Nadal, M., Kaczmarska, Z., Machón, C., Álvarez, M., Alberício, F., & Coll, M. (2018) · ACS Omega · doi:10.1021/acsomega.8b01472 · Cited by 12
Calmels, C., de Soultrait, V. R., Caumont, A., Desjobert, C., Faure, A., Fournier, M., Tarrago-Litvak, L., & Parissi, V. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh298 · Cited by 18
“Mn2+ is compatible with a wider range of reactive group geometries than Mg2+, and thus Mn2+-catalyzed IN reactions and inhibitions may be less sensitive to changes in reactive group geometries.”
BackgroundInfluentialThe Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario
Renzi, G., Carta, F., & Supuran, C. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512187 · Cited by 12
“Moreover, the potential action of chelating two magnesium metal ions in their active sites by the two enzymes is carried out through the presence of key acid amino acids (i.e., D443, E478, D498, and D549 for the RNase H domain and D64, D116, and E152 for HIV-1 IN) [126].”
BackgroundInfluentialInhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles
Sanna, V., Youssef, M. F., Pala, N., Rogolino, D., Carcelli, M., Singh, P. K., Sanchez, T. W., Neamati, N., & Sechi, M. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00648 · Cited by 12
Engelman, A., & Cherepanov, P. (2020) · FEBS Journal · doi:10.1111/febs.15438 · Cited by 12
Pharmacophore-based database mining for probing fragmental drug-likeness of diketo acid analogues
Bąk, A., Magdziarz, T., & Polański, J. (2012) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2011.645875 · Cited by 11
“, for binding two divalent cations by IN inhibitors are given in Figure 2(a) [36].”
BackgroundReduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance
Dewdney, T. G., Wang, Y., Kovari, I. A., Reiter, S. J., & Kovari, L. C. (2013) · Journal of Structural Biology · doi:10.1016/j.jsb.2013.07.008 · Cited by 16
HIV-1 Integrase Strand Transfer Inhibitors Stabilize an Integrase–Single Blunt-Ended DNA Complex
Bera, S., Pandey, K. K., Vora, A. C., & Grandgenett, D. P. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.043 · Cited by 13
Rostami, M. R., Sirous, H., Zabihollahi, R., Aghasadeghi, M. R., Sadat, S. M., Namazi, R., Saghaie, L., Memarian, H. R., & Fassihi, A. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1443-4 · Cited by 12
“It is believed that the IN strand transfer step inhibitors (INSTIs) bind to the acceptor DNA site of the enzyme and act by sequestering the metal ions bound in the IN active site to form a ligand–Mg–IN complex (Grobler et al., 2002; Kawasuji et al., 2006; Marchand et al., 2003).”
An Overview of Antiretroviral Agents for Treating HIV Infection in Paediatric Population
Melo, R., Lemos, A., Preto, A. J., Bueschbell, B., Matos‐Filipe, P., Barreto, C. A. V., de Almeida, J. G., Silva, R. D. M., Correia, J. D. G., & Moreira, I. S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180904123549 · Cited by 11
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
Giacomelli, A., Pezzati, L., & Rusconi, S. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1782737 · Cited by 11
“They each inhibit the strand transfer reaction by binding catalytic metal cations, thus blocking the intasome active site and displacing the 3ʹ OH ends [139,140].”
BackgroundPurification of untagged HIV-1 reverse transcriptase by affinity chromatography
Lu, M., Ngo, W., Mei, Y., Munshi, V., Burlein, C., Loughran, M. H., Williams, P. D., Hazuda, D. J., Miller, M. D., Grobler, J. A., et al. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.01.001 · Cited by 11
Self-citationXu, Y., Zeng, C., Li, X., Zhong, R., & Zeng, Y. (2006) · Chinese Journal of Chemistry · doi:10.1002/cjoc.200690203 · Cited by 11
Chi, G., Nair, V., Семенова, Е. А., & Pommier, Y. G. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.009 · Cited by 11
Effect of organic ligands with conjugated π‐bonds on the structure of iodine–α‐dextrin complexes
Yuldasheva, G. A., Zhidomirov, G. M., & Ilin, A. I. (2012) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.70 · Cited by 11
Hobaika, Z., Zargarian, L., Maroun, R. G., Mauffret, O., Burke, T. R., & Fermandjian, S. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0098-2 · Cited by 14
“The carboxylate group next to the diketo is also involved in the divalent cation chelation [21].”
Inhibitors of human immunodeficiency virus integration
Hazuda, D. J., & Young, S. D. (2003) · Advances in antiviral drug design · doi:10.1016/s1075-8593(03)04002-4 · Cited by 11
Self-citationEgbertson, M. S., Anthony, N. J., & Summa, V. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch14 · Cited by 11
Self-citationSangeetha, B., Muthukumaran, R., & Ramaswamy, A. (2013) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2013.792870 · Cited by 9
“Such inhibitors show strong preference towards inhibiting strand transfer reaction than the 3’-processing [8].”
BackgroundUnprocessed Viral DNA Could Be the Primary Target of the HIV-1 Integrase Inhibitor Raltegravir
Ammar, F. F., Abdel‐Azeim, S., Zargarian, L., Hobaika, Z., Maroun, R. G., & Fermandjian, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040223 · Cited by 11
Investigation of the structural requirement for inhibiting HIV integrase: QSAR study
Dessalew, N. (2009) · Acta Pharmaceutica · doi:10.2478/v10007-009-0006-y · Cited by 10
Strain-specific effect on biphasic DNA binding by HIV-1 integrase
Hill, K. J., Rogers, L. C., Njenda, D. T., Burke, D. H., Sarafianos, S. G., Sönnerborg, A. B., Neogi, U., & Singh, K. (2018) · AIDS · doi:10.1097/qad.0000000000002078 · Cited by 10
“INSTIs preferably bind to the integrase/DNA complex [10], suggesting that INSTI efficacy may depend upon DNA binding to integrase.”
Integrase inhibitors in salvage therapy regimens for HIV-1 infection
Koelsch, K. K., & Cooper, D. A. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328331b526 · Cited by 10
Messi, A. N., Bonnet, S. L., Owona, B. A., Wilhelm, A., Kamto, E. L. D., Ndongo, J. T., Siwe‐Noundou, X., Poka, M., Demana, P. H., Krause, R. W. M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081701 · Cited by 9
“Evaluation of Anti-HIV Integrase Assay The HIV-1 Integrase strand transfer inhibition assay was adapted from previously described methods [20,21].”
MethodLuo, Z., Zhao, Y. C., Ma, C., Li, Z., Xu, X., Hu, L., Huang, N., & He, H.-Q. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400390 · Cited by 9
The total synthesis of fukiic acid, an HIV-1 integrase inhibitor
Queffélec, C., Bailly, F., Mbemba, G., Mouscadet, J. F., Debyser, Z., Witvrouw, M., & Cotelle, P. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.12.013 · Cited by 10
Role of raltegravir in the management of HIV-1 infection
Hicks, C. B., & Okeke (2011) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s13985 · Cited by 9
Ferro, S., Grazia, S. D., Luca, L. D., Barreca, M. L., Debyser, Z., & Chimirri, A. (2009) · Heterocycles · doi:10.3987/com-08-11573 · Cited by 9
Pala, N., Esposito, F., Tramontano, E., Singh, P. K., Sanna, V., Carcelli, M., Haigh, L. D., Satta, S., & Sechi, M. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00009 · Cited by 9
Raup‐Konsavage, W. M., Sudol, M., & Katzman, M. (2008) · Virology · doi:10.1016/j.virol.2008.07.001 · Cited by 11
Kim, J., & Chong, Y. (2006) · Molecular Simulation · doi:10.1080/08927020601007538 · Cited by 9
“Biological activity (IC50) of ADK analogues [18,19].”
BackgroundInhibition of HIV-1 integrase by modified oligonucleotides: Optimization of the inhibitor structure
Prikazchikova, T. A., Volkov, E. M., Zubin, E. M., Романова, Е. А., & Gottikh, M. (2007) · Molecular Biology · doi:10.1134/s0026893307010165 · Cited by 9
Schooley, R. T. (2004) · Elsevier eBooks · doi:10.1016/b978-012764051-8/50033-0 · Cited by 10
Zeng, C., Li, X., Yan, H., & Zhong, R. (2007) · Chinese Journal of Chemistry · doi:10.1002/cjoc.200790219 · Cited by 8
He, T., Edwards, T. C., Xie, J., Aihara, H., Geraghty, R. J., & Wang, Z. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00203 · Cited by 8
Sirous, H., Zabihollahi, R., Aghasadeghi, M. R., Sadat, S. M., Saghaie, L., & Fassihi, A. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1289-1 · Cited by 10
“They have been emerged as potent inhibitors for two divalent metalrelated enzymatic activities of both enzymes which initiate with endonucleolytic phosphodiester hydrolysis (ShawReid et al., 2003; Grobler et al., 2002).”
InfluentialHIV-1 Integrase Drug Discovery Comes of Age
Demeulemeester, J., Maeyer, M. D., & Debyser, Z. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2013_33 · Cited by 9
Vandurm, P., Cauvin, C., Guiguen, A., Georges, B., Van, K. L., Martinelli, V., Cardona, C., Mbemba, G., Mouscadet, J. F., Hevesi, L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.044 · Cited by 8
Manganese(II) Oxidizing Bacteria as Whole-Cell Catalyst for β-Keto Ester Oxidation
Guo, J., Guo, H., Liu, J., Zhong, F., & Wu, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051709 · Cited by 8
“putida MnB1 was fundamentally accomplished via multicopper oxidase‐catalyzed oxidation of Mn(II) into Mn(VI) in cell extracts within its active center with three Cu(II) sites [34–36], and the β‐keto ester is known to chelate divalent metal ions, we speculate that compound 1 might potentially act as a multicopper oxida…”
BackgroundInfluentialSun, Q., Vijayan, R. S. K., Levy, R. M., & Deng, N. (2020) · Protein Science · doi:10.1002/pro.4004 · Cited by 7
Dissecting Tn5 Transposition Using HIV-1 Integrase Diketoacid Inhibitors
Czyż, A., Stillmock, K. A., Hazuda, D. J., & Reznikoff, W. S. (2007) · Biochemistry · doi:10.1021/bi7006542 · Cited by 8
“the DKA compounds binding to IN (15) to explain our”
BackgroundSelf-citationHIV-1 integrase inhibitors as new components of antiviral therapy
Prikazchikova, T. A., Sycheva, A. M., Agapkina, Y. Y., Александров, Д. А., & Gottikh, M. (2008) · Russian Chemical Reviews · doi:10.1070/rc2008v077n05abeh003779 · Cited by 9
Zeng, J., LÜ, X., Zeng, C., Hu, L., & Zhong, R. (2009) · Chinese Journal of Chemistry · doi:10.1002/cjoc.200990162 · Cited by 9
Inhibitors of human immunodeficiency virus type I integration
Hazuda, D. J. (2006) · Current Opinion in HIV and AIDS · doi:10.1097/01.coh.0000221594.57035.55 · Cited by 9
Self-citationInhibiting HCMV pUL89-C Endonuclease with Metal-Binding Compounds
Jagtap, A. D., Geraghty, R. J., & Wang, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01280 · Cited by 7
Drug-target interactions that involve the replacement or displacement of magnesium ions
Meanwell, N. A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.002 · Cited by 7
Brief Histories of Retroviral Integration Research and Associated International Conferences
Grandgenett, D. P., & Engelman, A. (2024) · Viruses · doi:10.3390/v16040604 · Cited by 8
“As had been concluded from prior solution-based measures of DKAs with HIV-1 IN [126], drug heteroatoms engaged the DDE-coordinated divalent metal ions.”
MethodYan, J., Wu, H., Tom, T., Brodsky, O., & Maegley, K. A. (2011) · American Journal of Analytical Chemistry · doi:10.4236/ajac.2011.26073 · Cited by 9
Pawar, R., Das, T., Mishra, S. K., Nutan, N., Pancholi, B., Sk, G., & Bhat, S. V. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.014 · Cited by 7
Komissarov, V. V., Panova, N., & Kritzyn, A. M. (2008) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162008010093 · Cited by 7
Egbertson, M. S., Wai, J. S. M., Cameron, M. J., & Hoerrner, R. S. (2011) · Wiley eBooks · doi:10.1002/9780470929353.ch12 · Cited by 8
Self-citationRaltegravir flexibility and its impact on recognition by the HIV‐1 IN targets
Arora, R., de Beauchêne, I. C., Polański, J., Laine, É., & Tchertanov, L. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2277 · Cited by 7
“…(IC50 values) in cellular antiviral and recombinant enzyme assays, kinetic analysis and slow-binding inhibition of IN-catalyzed ST reaction (Hazuda et al., 2000; Grobler et al., 2002; Copeland et al., 2006; Markowitz et al., 2006; Dicker et al., 2008; Garvey et al., 2009; Hightower et al., 2011).”
Background3-O-Arylmethylgalangin, a novel isostere for anti-HCV 1,3-diketoacids (DKAs)
Lee, H. S., Park, K., Lee, B., Kim, D., & Chong, Y. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.021 · Cited by 7
Khoury, L. E., Piquemal, J., Fermandjian, S., Maroun, R. G., Gresh, N., & Hobaika, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.001 · Cited by 8
Molecular Docking Study of Four Chromene Derivatives as Novel HIV-1 Integrase Inhibitors
Arslan, N. (2019) · Journal of the Turkish Chemical Society Section A Chemistry · doi:10.18596/jotcsa.478772 · Cited by 7
“Therefore, they are considered as potent inhibiting proteins which bear divalent metals which are involved in the hydrolysis of endonucleolytic phosphodiesters (8-9).”
Background
Metadata
- Authors
- Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J. S., Young, S., Vacca, J., & Hazuda, D. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Tufts University (US)
- Corresponding author
- Hazuda, Daria J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-05-07
- Volume
- 99
- Issue
- 10
- Pages
- 6661-6666
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC124459
- OpenAlex
- W2117959947
- Cited by
- 399
- References
- 32
- Citations by year
- 2026: 3 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 4 · 2018: 13 · 2017: 8 · 2016: 12 · 2015: 18 · 2014: 17 · 2013: 18 · 2012: 26
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HIV-1 integrase, strand transfer inhibition, metal-dependent enzyme activity, magnesium cofactor, carboxylate binding, reverse transcription, inhibitor mechanism of action
- MeSH terms
- Binding, Competitive, Humans, Ligands, Magnesium, Manganese, Models, Chemical, Phosphotransferases, Styrenes, Molecular Structure, HIV-1, HIV Long Terminal Repeat, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Streptavidin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.